ATE210440T1 - Behandlung von tumoren mit verbindungen mit einer rxr-retinoid agonistische wirkung - Google Patents

Behandlung von tumoren mit verbindungen mit einer rxr-retinoid agonistische wirkung

Info

Publication number
ATE210440T1
ATE210440T1 AT94911529T AT94911529T ATE210440T1 AT E210440 T1 ATE210440 T1 AT E210440T1 AT 94911529 T AT94911529 T AT 94911529T AT 94911529 T AT94911529 T AT 94911529T AT E210440 T1 ATE210440 T1 AT E210440T1
Authority
AT
Austria
Prior art keywords
retinoid
rxr
tumors
compounds
treatment
Prior art date
Application number
AT94911529T
Other languages
English (en)
Inventor
Peter A J Davies
Roshantha A Chandraratna
Original Assignee
Allergan Inc
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, Univ Texas filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE210440T1 publication Critical patent/ATE210440T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
AT94911529T 1993-03-11 1994-03-10 Behandlung von tumoren mit verbindungen mit einer rxr-retinoid agonistische wirkung ATE210440T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/029,801 US5399586A (en) 1993-03-11 1993-03-11 Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
PCT/US1994/002577 WO1994020093A1 (en) 1993-03-11 1994-03-10 Treatment of tumors with compounds having rxr retinoid receptor agonist activity

Publications (1)

Publication Number Publication Date
ATE210440T1 true ATE210440T1 (de) 2001-12-15

Family

ID=21850946

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94911529T ATE210440T1 (de) 1993-03-11 1994-03-10 Behandlung von tumoren mit verbindungen mit einer rxr-retinoid agonistische wirkung

Country Status (9)

Country Link
US (1) US5399586A (de)
EP (3) EP0909560A3 (de)
JP (1) JPH08509705A (de)
CN (1) CN1080117C (de)
AT (1) ATE210440T1 (de)
AU (1) AU678823B2 (de)
CA (1) CA2157798A1 (de)
DE (1) DE69429427T2 (de)
WO (1) WO1994020093A1 (de)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264578A (en) 1987-03-20 1993-11-23 Allergan, Inc. Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
US5272156A (en) * 1989-09-19 1993-12-21 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5183827A (en) * 1989-09-19 1993-02-02 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5264456A (en) * 1989-12-29 1993-11-23 Allergan, Inc. Acetylenes disubstituted with a furyl group and a substituted phenyl group having retinoid like activity
US5968989A (en) * 1991-12-18 1999-10-19 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US7056954B2 (en) * 1991-12-18 2006-06-06 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5962731A (en) * 1992-04-22 1999-10-05 Ligand Pharmaceuticals Incorporated Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5455265A (en) 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US6172115B1 (en) 1993-02-11 2001-01-09 Allergan Sales, Inc. Method for preventing onset of restenosis after angioplasty employing an RXR-specific retinoid
DE4319506A1 (de) * 1993-06-12 1994-12-15 Boehringer Mannheim Gmbh Verfahren zum Nachweis metabolisch markierter DNA
US5475022A (en) * 1993-10-18 1995-12-12 Allergan, Inc. Phenyl or heteroaryl and tetrahydronaphthyl substituted diene compounds having retinoid like biological activity
US5426118A (en) * 1993-12-30 1995-06-20 Allergan, Inc. [4-(1,2-epoxycyclohexanyl)but-3-en-1-ynyl]aromatic and heteroaromatic acids and derivatives having retinoid-like biological activity
EP0711356A4 (de) * 1994-05-26 1999-11-24 New York Medical College Nachweis von in dns eingebauten halogenierten vorläufern
US5648514A (en) * 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
US5599967A (en) * 1994-12-29 1997-02-04 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl of heteroaryl group having retinoid-like biological activity
US5543534A (en) * 1994-12-29 1996-08-06 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
US5534641A (en) * 1994-12-29 1996-07-09 Allergan Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5618943A (en) * 1994-12-29 1997-04-08 Allergan Acetylenes disubstituted with a 5 OXO substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5514825A (en) * 1994-12-29 1996-05-07 Allergan, Inc. Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
CA2218685A1 (en) * 1995-04-21 1996-10-24 Ligand Pharmaceuticals Incorporated Inhibition of apoptosis in cells expressing fas-ligand following activation
US6025388A (en) 1995-04-26 2000-02-15 Allergan Sales, Inc. Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids
US5616712A (en) * 1995-05-16 1997-04-01 Allergan Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-thio-1,2,3,4-tetrahdroquinolinyl, 2-alkylthio-3,4-dihydroquinolinyl or 2-alkoxy-3,4-dihydroquinolinyl group having retinoid-like biological activity
US5675033A (en) * 1995-06-06 1997-10-07 Allergan 2,4-pentadienoic acid derivatives having retinoid-like biological activity
US5917082A (en) * 1995-06-06 1999-06-29 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having retinoid-like biological activity
FR2735370B1 (fr) * 1995-06-19 1997-07-18 Cird Galderma Procede pour identifier des composes agonistes des recepteurs rxrs
EP0851939A4 (de) * 1995-08-30 2001-02-28 New York Medical College Methode zur markierung von dna-enden mit halogenierten nukleotiden und deren nachweis mit antikörpern
US6008204A (en) 1995-09-01 1999-12-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5952345A (en) * 1995-09-01 1999-09-14 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5958954A (en) * 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US6942980B1 (en) 1995-09-01 2005-09-13 Allergan, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US6218128B1 (en) 1997-09-12 2001-04-17 Allergan Sales, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
WO1997010813A1 (en) 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Ppar gamma antagonists for treating obesity
BR9610875A (pt) 1995-10-06 1999-07-13 Ligand Pharm Inc Modulares rxr seletivos - dimeros e processos para seu uso
FR2739777B1 (fr) * 1995-10-11 1997-11-14 Cird Galderma Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
AU7598596A (en) * 1995-11-01 1997-05-22 Allergan, Inc. Sulfides, sulfoxides and sulfones disubstituted with a tetrahydronaphthalenyl, chromanyl, thiochromanyl or tetrahydroquinolinyl and substituted phenyl or heteroaryl group, having retinoid-like biological activity
US5675024A (en) 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US5663357A (en) * 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
US5688957A (en) * 1995-12-29 1997-11-18 Allergan (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!aryl and (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!heteroaryl carboxylic acids and esters having retinoid-like biological activity
US20030219832A1 (en) * 1996-03-11 2003-11-27 Klein Elliott S. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
EP0923738A1 (de) * 1996-06-11 1999-06-23 Advanced Research & Technology Institute Verfahren und zubereitungen für die verwendung von apurinischen/apyrimidinischen endonukleasen
US6406917B1 (en) 1996-06-11 2002-06-18 Advanced Research And Technology Institute Methods and compositions for the use of apurinic/apyrimidinic endonucleases
US5741896A (en) 1996-06-21 1998-04-21 Allergan O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US6555690B2 (en) 1996-06-21 2003-04-29 Allergan, Inc. Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5747542A (en) * 1996-06-21 1998-05-05 Allergan Oxo-substituted tetrahydronaphthalene derivatives having retinold and/or retinoid antagonist-like biological activity
US5808124A (en) * 1996-06-21 1998-09-15 Allergan O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5723666A (en) * 1996-06-21 1998-03-03 Allergan Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5773594A (en) 1996-06-21 1998-06-30 Allergan Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5763635A (en) * 1996-06-21 1998-06-09 Allergan Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
CA2263817A1 (en) * 1996-08-28 1998-03-05 Centre National De La Recherche Scientifique Therapeutic combinations of rar antagonists and rxr agonists and use thereof
US5912168A (en) * 1996-08-30 1999-06-15 Genesis Research & Development Corporation Limited CD95 regulatory gene sequences
US20020151063A1 (en) * 1996-08-30 2002-10-17 Annette Lasham Methods for modulating apoptotic cell death
FR2752734B1 (fr) 1996-09-02 1998-11-06 Cird Galderma Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US6646008B1 (en) * 1996-12-31 2003-11-11 The Salk Institute For Biological Studies Treatment of disease states which result from neoplastic cell proliferation using PPAR-γ activators and compositions useful therefor
US5760276A (en) * 1997-03-06 1998-06-02 Allergan Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity
US6037488A (en) 1997-04-19 2000-03-14 Allergan Sales, Inc. Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
EP0977892A1 (de) 1997-04-24 2000-02-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methoden und zusammensetzungen zur regulation der expresssion von matrix-metalloproteinase genen
US5919970A (en) * 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
EP1003493A4 (de) * 1997-07-29 2002-03-27 Bristol Myers Squibb Co Verwendung von selektion rxr agonisten zur vorbeugung chirurgischen adhäsionen
US6521814B1 (en) 1997-12-22 2003-02-18 Institut National De La Santa Et De La Recherche Medicale Use of ligands for treatment of diseases responsive to retinoids
AU4676999A (en) * 1998-06-12 1999-12-30 Ligand Pharmaceuticals, Inc. Treatment of anti-estrogen resistant breast cancer using rxr modulators
AU771224B2 (en) 1998-07-13 2004-03-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
SI1107795T1 (en) 1998-09-04 2003-06-30 The Regents Of The University Of Michigan Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis
WO2000030628A2 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Method of inhibiting angiogenesis
US6624154B1 (en) * 1999-04-23 2003-09-23 Bristol-Myers Squibb Company Compositions and methods for treatment of hyperproliferative diseases
AU773928B2 (en) * 1999-04-23 2004-06-10 Bristol-Myers Squibb Company Compositions and methods for treatment of hyperproliferative diseases
US20040228871A1 (en) * 1999-06-03 2004-11-18 Tayyaba Hasan Treatment and analysis of proliferative disorders
PL353792A1 (en) 1999-08-27 2003-12-01 Ligand Pharmaceuticals Incorporatedligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US6667313B1 (en) 1999-08-27 2003-12-23 Ligand Pharmaceuticals Inc. 8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
WO2001019770A2 (en) 1999-09-14 2001-03-22 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile
DK1248604T4 (da) 2000-01-21 2012-05-21 Novartis Ag Kombinationer indeholdende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
US6355446B1 (en) * 2000-03-24 2002-03-12 Ludwig Institute For Cancer Research DocosahexAenoic acid as retinoid X-receptor ligand and uses thereof
AU4866201A (en) * 2000-04-13 2001-10-30 Pierre Chambon Compositions and methods for use in modulating immune system function
US6403810B2 (en) * 2000-07-10 2002-06-11 Hoffmann-La Roche Inc. Thiophene derivatives
EP1385549A2 (de) * 2001-03-12 2004-02-04 Novartis AG Kombination aus nateglinid oder repaglinid mit mindestens einer weiteren antidiabetischen verbindung
CA2438586A1 (en) 2001-03-14 2002-09-19 Eli Lilly And Company Retinoid x receptor modulators
AU2002333655A1 (en) * 2001-09-25 2003-04-07 Smithkline Beecham Corporation Bicyclic heterocycles as rxr ligands
EP1496879A4 (de) * 2002-04-05 2008-06-18 Univ Utah Res Found Regulierung einer neuen kolon-spezifischen retinol-dehydrogenase durch apc und cdx2
EP1356820A1 (de) * 2002-04-26 2003-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) DNA-Impfstoff kombiniert mit einen Apoptoneauslöser von Tumorzellen
US7572442B2 (en) 2002-07-15 2009-08-11 Board Of Regents, The University Of Texas System Selected antibody compositions for binding to aminophospholipids
US8431396B2 (en) 2003-03-21 2013-04-30 The Cleveland Clinic Foundation Anti-angiogenic peptides
JP2007525188A (ja) 2003-05-16 2007-09-06 インターミューン インコーポレイテッド 合成ケモカイン受容体リガンドおよびその使用方法
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
ES2410587T3 (es) 2004-01-22 2013-07-02 University Of Miami Formulaciones tópicas de coenzima Q10 y métodos de uso
US9050310B2 (en) 2004-06-25 2015-06-09 Minas Theodore Coroneo Treatment of ocular lesions
JPWO2007049542A1 (ja) * 2005-10-24 2009-04-30 大鵬薬品工業株式会社 ＲＡＲ−α作動薬の有効性の予測方法
NZ569535A (en) * 2005-12-30 2011-12-22 Revance Therapeutics Inc Arginine heteromers for topical administration
US8541467B2 (en) 2006-08-16 2013-09-24 Action Medicines, S.L. Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ
CN109503446B (zh) * 2007-01-15 2021-08-20 于崇曦 维生素a酸类和类维生素a酸化合物的前药
MX2010005104A (es) 2007-11-09 2010-08-04 Peregrine Pharmaceuticals Inc Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
US20090209601A1 (en) * 2008-02-15 2009-08-20 Wyeth Use of rxr agonists for the treatment of osteoarthritis
US8772273B2 (en) * 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
US20160263189A1 (en) 2013-10-23 2016-09-15 Acadia Pharmaceuticals Inc. Treatment of a neurodegenerative disease or disorder
US11045441B2 (en) 2015-10-13 2021-06-29 Wisconsin Alumni Research Foundation Use of retinoic acid and analogs thereof to treat central neural apneas
CN112823023B (zh) * 2018-08-10 2024-04-12 桑福德伯纳姆普利斯医学发现研究所 肿瘤相关巨噬细胞的结合分子及使用方法
EP3887401A2 (de) 2018-11-26 2021-10-06 Denali Therapeutics Inc. Verfahren zur behandlung eines dysregulierten lipidmetabolismus

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4085091A (en) * 1976-12-16 1978-04-18 E. I. Dupont De Nemours And Company Thermally stable, rigid polyesters from thermally stable, rigid dibasic acids and aromatic dihydroxy compounds
US4326055A (en) * 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
EP0047817A3 (de) * 1980-08-14 1982-05-26 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Hydrierte Naphthaline, deren Herstellung und Verwendung sowie derartige Naphthaline enthaltende Gemische
DE3202118A1 (de) * 1982-01-23 1983-07-28 Basf Ag, 6700 Ludwigshafen Substituierte vinylbenzoesaeure-derivate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
EP0130795B1 (de) * 1983-07-05 1988-11-23 Pfizer Inc. Karbonsäure-Derivate verwendbar bei der Verhütung der Zersetzung von Knorpeln
DE3407510A1 (de) * 1984-03-01 1985-09-05 A. Nattermann & Cie GmbH, 5000 Köln (omega)-aryl-alkylthienylalk(a,e)nsaeuren und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
JPS60222445A (ja) * 1984-04-19 1985-11-07 Yoshitomi Pharmaceut Ind Ltd フタル酸化合物
JPS6122046A (ja) * 1984-07-07 1986-01-30 Koichi Shiyudo スチルベン誘導体
LU85544A1 (fr) * 1984-09-19 1986-04-03 Cird Derives heterocycliques aromatiques,leur procede de preparation et leur application dans les domaines therapeutique et cosmetique
DE3434946A1 (de) * 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen Diarylacetylene, ihre herstellung und verwendung
LU86022A1 (fr) * 1985-07-25 1987-02-04 Cird Derives aromatiques polycyliques,leur procede de preparation et leur application dans les domaines pharmaceutique et cosmetique
IL80270A0 (en) * 1985-10-11 1987-01-30 Cird Naphthalene derivatives,their preparation and pharmaceutical compositions containing them
LU86351A1 (fr) * 1986-03-12 1987-11-11 Oreal Composes benzopyrannyl et benzothiopyrannyl benzoiques,leur procede de preparation et leur utilisation en cosmetique et en medecine humaine et veterinaire
DE3615157A1 (de) * 1986-05-05 1987-11-12 Schwabe Willmar Gmbh & Co 5-arylalkyl-4-alkoxy-2(5h)-furanone, zwischenprodukte und verfahren zu ihrer herstellung sowie ihre anwendung als therapeutische wirkstoffe
ZW7487A1 (en) * 1986-05-23 1987-12-16 Hoffmann La Roche Tetrahydronaphthaline and indane derivatives
US5084476A (en) * 1986-07-15 1992-01-28 Hoffmann-La Roche Inc. Tetrahydronaphthalene and indane derivatives
ZW10287A1 (en) * 1986-07-15 1988-01-13 Hoffmann La Roche Tetrahydronaphthaline and indane derivatives
US4739098A (en) * 1986-09-22 1988-04-19 Allergan, Inc. Ethynylphenyl-containing retinoic acid derivatives
CA1305480C (en) * 1987-03-20 1992-07-21 Roshantha A.S. Chandraratna Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5089509A (en) * 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US4810804A (en) * 1987-03-26 1989-03-07 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid-like activity
US4994491A (en) * 1988-12-14 1991-02-19 Molecular Design International Dermal uses of trans-retinoids for the treatment of cancer
KR0139216B1 (ko) * 1988-04-11 1998-05-01 제임스 엠. 캐내지 레티노이드 유사활성을 갖는 페놀 또는 벤조산의 테트랄린 에스테르
US5015658A (en) * 1988-06-29 1991-05-14 Allergan, Inc. Thiochroman esters of phenols and terephthallates having retinoid-like activity
US4895868A (en) * 1988-06-29 1990-01-23 Allergan, Inc. Thiochroman esters of phenols and terephthallates having retinoid-like activity
AU626881B2 (en) * 1988-07-14 1992-08-13 F. Hoffmann-La Roche Ag Benzofused heterocyclics used as pharmaceuticals
US5049584A (en) * 1988-12-14 1991-09-17 Molecular Design International Dermal uses of cis-retinoids for the treatment of cancer
JPH02193990A (ja) * 1989-01-20 1990-07-31 Taisho Pharmaceut Co Ltd チオフェンカルボン酸誘導体
US4992468A (en) * 1989-07-26 1991-02-12 Allergan, Inc. Phenylethenyl compounds having retinoid-like activity
US5068252A (en) * 1989-07-26 1991-11-26 Allergan, Inc. Methods of using phenylethenyl compounds having retinoid-like activity
US5053523A (en) * 1989-09-19 1991-10-01 Allergan, Inc. Ethynyl-chroman compounds
US5023341A (en) * 1989-09-19 1991-06-11 Allergan, Inc. Compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity
US5183827A (en) * 1989-09-19 1993-02-02 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5045551A (en) * 1989-09-19 1991-09-03 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US4980369A (en) * 1989-09-19 1990-12-25 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl or thiochromanyl group having retinoid-like activity
US5162546A (en) * 1989-09-19 1992-11-10 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5006550A (en) * 1989-12-29 1991-04-09 Allergan, Inc. Chroman esters of phenols and benzoic acids having retinoid-like activity
US5013744B1 (en) * 1989-12-29 1994-09-20 Allegran Inc Acetylenes disubstituted with a pyridinyl group and a substituted phenyl group having retinoid like activity
US5175185A (en) * 1989-12-29 1992-12-29 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a substituted phenyl group having retinoid like activity
US5202471A (en) * 1990-02-06 1993-04-13 Allergan, Inc. Alkyl, alkoxy and thioalkoxy substituted diphenyl acetylenes having retinoid like activity
US5134159A (en) * 1991-03-26 1992-07-28 Allergan, Inc. 7-chromanyl esters of phenols and benzoic acids having retinoid-like activity
EP0617614B1 (de) * 1991-12-18 1998-03-04 The Salk Institute For Biological Studies Mitteln zur modulierung von verfahren durch retinoid rezeptoren und dafür nützliche verbindungen
BR9306284A (pt) * 1992-04-22 1998-01-13 Ligand Pharm Inc Compostos tendo seletividade pra receptores de retinóides x
US5324840A (en) * 1992-06-11 1994-06-28 Allergan, Inc. Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors

Also Published As

Publication number Publication date
EP0909560A3 (de) 2002-05-22
JPH08509705A (ja) 1996-10-15
EP1159961A2 (de) 2001-12-05
EP0909560A2 (de) 1999-04-21
EP1159961A3 (de) 2002-05-22
CN1080117C (zh) 2002-03-06
WO1994020093A1 (en) 1994-09-15
US5399586A (en) 1995-03-21
CN1122105A (zh) 1996-05-08
DE69429427T2 (de) 2002-08-22
EP0688213B1 (de) 2001-12-12
AU6401494A (en) 1994-09-26
CA2157798A1 (en) 1994-09-15
EP0688213A1 (de) 1995-12-27
AU678823B2 (en) 1997-06-12
DE69429427D1 (de) 2002-01-24

Similar Documents

Publication Publication Date Title
DE69429427D1 (de) Behandlung von tumoren mit verbindungen mit einer rxr-retinoid agonistische wirkung
PT772600E (pt) Compostos de imidazolilo substituido nas posicoes 1 e 2 para o tratamento da inflamacao
DE69228000D1 (de) Behandlung von akne oder von folliculitis barbae
EA199900808A1 (ru) Бифенилсульфонамиды и их производные, модулирующие активность эндотелина
IT1114950B (it) Composizioni per il trattamento e la terapia di acne
BG60249B1 (bg) Тиазолово съединение за лечение на язви
DE10075033I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur Behandlung von Entzuendungen
EA199800626A1 (ru) Применение агониста ppar-гамма для лечения синдрома х
MX9701385A (es) Preparacion de producto combinado para usarse en enfermedades inmunologicas.
ES2022660B3 (es) Pulverizador portatil de liquido, especial para el tratamiento de la vegetacion
BR9914925A (pt) Processos para reduzir o crescimento de cabelo de mamìfero, para tratar uma área de pele, e, para produzir uma composição para inibir crescimento do cabelo de mamìfero, uso de um inibidor de fosfatase alcalina, e, composição usada para inibir crescimento de cabelo de mamìfero.
ATE20641T1 (de) Pharmazeutisches praeparat zur topischen behandlung von akne.
DK261490D0 (da) New pharmaceutical compound
NO820429L (no) Tetrahydronaftalin- og indanforbindelser
DE69803271D1 (de) Von einem aromatischen oder heteroaromatischen radikal substituierte biphenylderivate und diese enthaltende pharmaceutische und kosmetische compositionen
ATE317693T1 (de) Substituierte stilbene mit gefässschädigender aktivität
ES2092646T3 (es) Metanoantracenos como antagonistas de dopamina.
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
FI844491A7 (fi) Laite kasvaimien, karieksen ja muiden tautien ehkäisemiseksi ja hoitamiseksi lieventämällä huomattavasti kipuja käyttämällä sähkö- ja/tai magneettipulsseja.
MXPA03011270A (es) Uso de antagonistas rank para tratar cancer.
ES460621A1 (es) Procedimiento de sintesis de n-(1'-alil-2'-pirrolidilmetil)-2,3-dimetoxi-5-sulfamoilbenzamida.
NO902157L (no) Butensyrederivater for terapeutisk anvendelse.
AR024082A1 (es) Sales antitranspirantes y metodos para su preparacion
MX9201258A (es) Compuestos para el tratamiento del cancer y procedimiento para su preparacion.
ATE133860T1 (de) Tumor-nekrose-faktor-antagonist

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties